What is a potential risk associated with the use of depot medroxyprogesterone acetate (DMPA)?

• A. Decreased libido
• B. Bone density loss
• C. Increased fertility risks
• D. Irregular menstrual cycles

Answer: (B)

Depot medroxyprogesterone acetate (DMPA) is a hormonal contraceptive administered via injection that provides effective pregnancy prevention. One of the recognized potential risks associated with DMPA is bone density loss. This risk arises because the hormone progestin, which DMPA contains, can influence bone metabolism. Research has shown that long-term use of DMPA can lead to decreased bone mineral density, particularly in young women whose bones are still developing. The reduction in estrogen levels, which is associated with DMPA use, contributes to this effect, as estrogen plays a critical role in promoting bone health.

Other factors related to DMPA, such as decreased libido, increased fertility risks, and irregular menstrual cycles, may also occur but do not carry the same level of concern regarding significant long-term health implications as bone density loss does. While these side effects can impact quality of life and reproductive health, the concern about bone density loss emphasizes the importance of monitoring bone health in women who use DMPA, particularly for extended periods. Awareness of this risk allows healthcare providers and patients to make informed decisions regarding contraceptive options and to implement measures (like supplemental calcium and vitamin D) to help mitigate potential bone loss.